| miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes M Croset, F Pantano, CWS Kan, E Bonnelye, F Descotes, ... Cancer research 78 (18), 5259-5273, 2018 | 171 | 2018 |
| Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts M David, E Wannecq, F Descotes, S Jansen, B Deux, J Ribeiro, CM Serre, ... PloS one 5 (3), e9741, 2010 | 151 | 2010 |
| Validation of tumor‐associated macrophage ferritin light chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study P Jézéquel, L Campion, F Spyratos, D Loussouarn, M Campone, ... International journal of cancer 131 (2), 426-437, 2012 | 117 | 2012 |
| Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine F Descotes, N Kara, M Decaussin-Petrucci, E Piaton, F Geiguer, ... British journal of cancer 117 (4), 583-587, 2017 | 98 | 2017 |
| Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin A Fradet, H Sorel, L Bouazza, D Goehrig, B Dépalle, A Bellahcene, ... Cancer research 71 (17), 5728-5738, 2011 | 94 | 2011 |
| S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study A Chassevent, ML Jourdan, S Romain, F Descotes, M Colonna, ... Clinical cancer research 7 (4), 909-917, 2001 | 84 | 2001 |
| Predictive factors of outcome in poorly differentiated thyroid carcinomas C de la Fouchardière, M Decaussin-Petrucci, J Berthiller, F Descotes, ... European Journal of Cancer 92, 40-47, 2018 | 71 | 2018 |
| Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and … M David, J Ribeiro, F Descotes, CM Serre, M Barbier, M Murone, ... International journal of oncology 40 (4), 1133-1141, 2012 | 71 | 2012 |
| High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer A Berthier, S Seguin, AJ Sasco, JY Bobin, G De Laroche, J Datchary, ... British journal of cancer 102 (6), 1024-1031, 2010 | 67 | 2010 |
| Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy M Decaussin‐Petrucci, F Descotes, L Depaepe, V Lapras, ML Denier, ... Cytopathology 28 (6), 482-487, 2017 | 65 | 2017 |
| TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma C Bournaud, F Descotes, M Decaussin-Petrucci, J Berthiller, ... European Journal of Cancer 108, 41-49, 2019 | 59 | 2019 |
| Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population. F Descotes, JJ Pavy, GL Adessi Anticancer research 13 (1), 119-124, 1993 | 49 | 1993 |
| Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study S Romain, F Spyratos, F Descotes, A Daver, B Rostaing‐Puissant, ... International journal of cancer 87 (6), 860-868, 2000 | 47 | 2000 |
| The co-occurrence of an ovarian Sertoli-Leydig cell tumor with a thyroid carcinoma is highly suggestive of a DICER1 syndrome E Durieux, F Descotes, C Mauduit, M Decaussin, S Guyetant, ... Virchows Archiv 468, 631-636, 2016 | 40 | 2016 |
| High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients N Pernodet, F Hermetet, P Adami, A Vejux, F Descotes, C Borg, M Adams, ... Breast Cancer Research 14, 1-15, 2012 | 39 | 2012 |
| Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase … F Descotes, B Riche, S Saez, G De Laroche, J Datchary, P Roy, J André, ... Clinical breast cancer 8 (2), 168-177, 2008 | 39 | 2008 |
| Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer N Bossard, F Descotes, AG Bremond, Y Bobin, P De Saint Hilaire, ... Breast cancer research and treatment 82, 47-59, 2003 | 32 | 2003 |
| Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors L Paulet, A Trecourt, A Leary, J Peron, F Descotes, ... European Journal of Cancer 166, 87-99, 2022 | 31 | 2022 |
| Identification of Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Biomarker for Lysophosphatidic Acid Receptor Type 1 (LPA1) Activation in Human Breast … M David, D Sahay, F Mege, F Descotes, R Leblanc, J Ribeiro, P Clézardin, ... PLoS One 9 (5), e97771, 2014 | 31 | 2014 |
| Microarray gene expression profiling and analysis of bladder cancer supports the sub‐classification of T 1 tumours into T 1a and T 1b stages F Descotes, P Dessen, PP Bringuier, M Decaussin, PM Martin, M Adams, ... BJU international 113 (2), 333-342, 2014 | 27 | 2014 |
